Condition (MeSH)
Hemoglobin SC Disease
ClinicalTrials.gov lists 32 trials for Hemoglobin SC Disease or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
32 of the 32 trials are tagged with Hemoglobin SC Disease itself; the rest are tagged with a narrower condition beneath it.
When did Hemoglobin SC Disease trials start? (19)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 3
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2024 | 1 |
| 2021 | 2 |
| 2020 | 3 |
| 2019 | 3 |
| 2018 | 2 |
| 2017 | 3 |
| 2016 | 1 |
| 2015 | 2 |
| 2014 | 2 |
Showing 10 of 19 earlier years.
No forecast is made for this condition: it averages 0.2 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 32 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Hemoglobin SC Disease trials in? (7)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 5 |
| Phase 1/2 | 1 |
| Phase 2 | 8 |
| Phase 3 | 2 |
| Phase 4 | 1 |
| Not applicable | 12 |
| Observational | 3 |
How many Hemoglobin SC Disease trials are recruiting? (7)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 1 |
| Recruiting | 1 |
| Active, not recruiting | 1 |
| Completed | 17 |
| Terminated | 7 |
Showing 5 of 7 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Hemoglobin SC Disease trials? (4)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Novartis Pharmaceuticals | 2 |
| Sangart | 2 |
| Cardurion Pharmaceuticals, Inc. | 1 |
| Micelle BioPharma Inc | 1 |
Which drugs are being tested for Hemoglobin SC Disease? (2)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Busulfan | 3 |
| Crizanlizumab | 2 |
Interventions as named in the registry (13)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| HU - Hydroxyurea | 3 |
| SQ Fludarabine | 3 |
| NaCl 0.9% NS | 2 |
| Alemtuzumab s.c. | 2 |
| MP4CO | 2 |
Showing 5 of 13 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Hemoglobin SC Disease trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Sickle cell anaemia with crisis | 11 | 2 |
| COVID-19 | 8 | 1 |
| Pneumonia | 7 | 2 |
| Pulmonary embolism | 7 | 2 |
| Chest pain | 5 | 2 |
Showing 5 of 10 adverse events.
Which publications cover Hemoglobin SC Disease? (23)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Metabolic signatures of cardiorenal dysfunction in plasma from sickle cell patients as a function of therapeutic transfusion and hydroxyurea treatment. | Haematologica | 2023 | Yes |
| Neurocognitive functioning in preschool children with sickle cell disease. | Pediatric blood & cancer | 2022 | Yes |
| Impact of a paediatric-adult care transition programme on the health status of patients with sickle cell disease: study protocol for a randomised controlled trial (the DREPADO trial). | Trials | 2020 | Yes |
| Hemorheological alterations, decreased cerebral microvascular oxygenation and cerebral vasomotion compensation in sickle cell patients. | American journal of hematology | 2012 | Yes |
| The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi-centre CHAMPS trial. | British journal of haematology | 2011 | Yes |
Showing 5 of 23 publications.
Prevalence (2)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Sickle cell S-C disease | Point prevalence | Unknown | Worldwide | Not stated | Exact |
| Sickle cell S-C disease | Point prevalence | Unknown | Worldwide | Not stated | Exact |
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Sickle cell S-C disease | 251365 | Exact | Orphadata Science knowledge files, Product 1 |
| Sickle cell S-C disease | 251365 | Exact | Orphanet Rare Disease Ontology (ORDO) |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: sub-conditions in mesh.